Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Proliferative Diabetic Retinopathy

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

vitreous haemorrhage
tractional retinal detachment
active proliferative diabetic retinopathy.

Exclusion criteria

neovascular glaucoma
cataract
combined traction and rhegmatogenous RD

Treatment and study plan

Bevacizumab

Drug

SHAM

Other

Sponsors and collaborators

Lead sponsor

University of Campania Luigi Vanvitelli

Other

Collaborators

Napoli CTO Hospital

Registry information

Important dates

First posted: Dec 4, 2009
Registry last updated: Dec 4, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed